Fidelity
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Highlights from AGN’s 1Q11 CC:

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 451
Posts 78,570
Boards Moderated 20
Alias Born 09/05/02
160x600 placeholder
U.S. Stocks Fall; PMI, Home Sales Disappoint
U.S. stocks deepened losses after a pair of disappointing reports on manufacturing and the housing market, putting the S&P 500 and Nasdaq Composite on track to break their six-day winning streaks.
Top Equities Stories Of The Day
Ackman: Poison Pill Is Way for Allegan to Explore Alternatives -CNBC
Comcast Profit Rises 30% on Video Subscriber Additions-- 2nd update
Client Balances at Morgan Stanley Wealth Management Near Merrill Lynch
Apple, Facebook, Amazon Off As Techs Retreat
Correction to AT&T Earnings Story
Correction to Yum Earnings Story
Ford Operating Chief Mark Fields to Become CEO -- Update
Citigroup Shareholders Approve Leaders' Pay -- 4th Update
DewDiligence Member Level  Wednesday, 05/04/11 03:11:09 PM
Re: DewDiligence post# 114167
Post # of 177192 
Highlights from AGN’s 1Q11 CC:

• 2011 non-GAAP EPS guidance raised by $0.02 to a range $3.56-3.62 (+14% YoY).

• Botox: $365M, +9% YoY in local currencies. Dysport, the main competitor, remains stuck at a 17% procedure share in US cosmetic indications and a de minimis share in US medical indications share (#msg-62706265, #msg-49695053). Xeomin’s US market share in also de minimis. Worldwide in all indications, Botox has an 80% market share.

• Juvederm franchise: $88M, +47% YoY in local currencies, due in part to inventory stocking for a promotional program aimed at patients who used Botox and Juvederm.

• Latisse: $25M, +34% YoY, +47% QoQ in local currencies due to some inventory stocking. Although 1Q11 was on track with AGN’s forecast of 2011 sales of $100M, Latisse is clearly not ramping up as quickly as I expected when the product was approved in late 2008 (#msg-34424441).

• Only weak product was LapBand: $52M, -16% YoY in local currencies; however, LapBand retained a 73% global market share in the category. (JNJ has the rest.)

• Sales of all AGN products in Latin America increased 32% YoY in dollars, thanks in part to the stronger Brazilian Real.

15% of AGN’s overall sales are in emerging markets; CEO, David Pyott thinks this will go to 25-30% in the next five years.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (3) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist